Sitagliptin phosphate, an oral anti-diabetic drug, is prescribed for the treatment and management of type-2 diabetes mellitus in adults. The drug is either prescribed as a monotherapy or as a combined therapy with other anti-diabetic drugs. Sitagliptin phosphate lowers plasma glucose levels and regulates blood glucose and insulin levels. However, Sitagliptin phosphate is not indicated for type-1 diabetic patients.
No information available
No information available
No information available
Sitagliptin phosphate can cause serious pancreatitis, changes in urination, severe skin reaction, runny nose, sore throat, headache, nausea, diarrhoea or constipation, myalgia, arthralgia and paced heart beats.
Sitagliptin phosphate is contraindicated in patients with clinical history of pancreatitis and in dialysis-dependent renal patients.
No information available
Sitagliptin phosphate may interact with insulin, oral anti-diabetic drugs, Probenecid, NSAIDs, aspirin, blood thinners, sulfa drugs, MAOIs and beta-blockers.
No information available
For Diabetes Type 2 (Adults):
Consider oral administration of 100 mg of Sitagliptin phosphate, once daily
Sitagliptin phosphate can be taken before or after food intake
USFDA pregnancy category B. Sitagliptin phosphate may not cause harm to an unborn foetus. Before Sitagliptin phosphate treatment, the patient should discuss with the physician, if they are planning for a pregnancy.
It is unclear whether the drug could pass through the breast milk to a breast feeding a baby. Consult your physician before taking Sitagliptin phosphate, if you are nursing mother.
Sitagliptin phosphate should not be given to children younger than 18 years old without a Paediatrician’s advice.
No specific information
No specific information
Store at 20-25°C.
Store at 20-25°C.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.